Dr Tim Rattay

NIHR Clinical Lecturer

School/Department: Genetics and Genome Biology, Department of

Telephone: +44 (0)116 252 5825



Dr Tim Rattay is a Clinical Lecturer in Surgery with an honorary appointment at University Hospitals of Leicester NHS Trust. After core surgical training in the West Midlands and a medical teaching fellowship at the University of Warwick, Dr Rattay entered the NIHR joint clinical-academic training programme in the East Midlands Deanery.

Dr Rattay completed an academic clinical fellowship and subsequently obtained his PhD at the University of Leicester, funded by an NIHR Doctoral Research Fellowship.

Dr Rattay works clinically at Glenfield Hospital in Leicester, one of the largest-volume breast cancer centres in the UK.


Breast cancer is the most common cancer in the UK, accounting for over 50,000 new cases per year. Thankfully, the vast majority of breast cancers are treatable. Approximately 800,000 women previously diagnosed with breast cancer were estimated to be alive in the UK in 2020 - a figure predicted to rise to over 1.2 million by 2030. 

Surgery and radiotherapy are the most commonly used breast cancer treatments. However about 1 in 5 patients will experience moderate to severe side-effects (toxicity) from treatment. Dr Rattay’s main research interests are in the prediction and reduction of treatment toxicity in the breast. Dr Rattay’s research is focused on validating clinical and molecular predictors of toxicity as well as discovering new predictors through genome-wide association studies, and Big Data and artificial intelligence (AI) approaches. Dr Rattay is also interested in applying qualitative research methodology to explore patients’ views on breast cancer treatments and personalised medicine.

Dr Rattay previously worked on the EU-funded REQUITE study and is currently the local principal investigator for the ERA-funded RADprecise study.

Other sources of funding are the National Institute for Health and care Research (NIHR), the Science and Technology Facilities Council (STFC) Global Challenge Network+ in Advanced Radiotherapy, and the Association of Breast Surgery.



A data science approach for early-stage prediction of Patient's susceptibility to acute side effects of advanced radiotherapy.
M Aldraimli, D Soria, D Grishchuck, S Ingram, R Lyon, A Mistry, J Oliveira, R Samuel, LEA Shelley, S Osman, MV Dwek, D Azria, J Chang-Claude, S Gutiérrez-Enríquez, MC De Santis, BS Rosenstein, D De Ruysscher, E Sperk, RP Symonds, H Stobart, A Vega, L Veldeman, A Webb, CJ Talbot, CM West, T Rattay and TJ Chaussalet. Computers in Biology and Medicine. 2021 Aug;135:104624.

Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity.
NR Franco, MC Massi, F Ieva, A Manzoni, AM Paganoni, P Zunino, L Veldeman, P Ost, V Fonteyne, CJ Talbot, T Rattay, A Webb, K Johnson, M Lambrecht, K Haustermans, G De Meerleer, D de Ruysscher, B Vanneste, E Van Limbergen, A Choudhury, RM Elliott, E Sperk, MR Veldwijk, C Herskind, B Avuzzi, B Noris Chiorda, R Valdagni, D Azria, MP Farcy-Jacquet, M Brengues, BS Rosenstein, RG Stock, A Vega, ME Aguado-Barrera, P Sosa-Fajardo, AM Dunning, L Fachal, SL Kerns, D Payne, J Chang-Claude, P Seibold, CML West and T Rancati. Radiotherapy and Oncology 2021 Jun;159:241-248.

External validation of a predictive model for acute skin radiation toxicity in the REQUITE breast cohort.
T Rattay, P Seibold, ME Aguado-Barrera, M Altabas, D Azria, GC Barnett, R Bultijnck, J Chang-Claude, A Choudhury, CE Coles, AM Dunning, RM Elliott, MP Farcy-Jacquet, S Gutiérrez-Enríquez, K Johnson, A Müller, G Post, T Rancati, V Reyes, BS Rosenstein, D De Ruysscher, MC de Santis, E Sperk, H Stobart, RP Symonds, B Taboada-Valladares, A Vega, L Veldeman, AJ Webb, CM West, R Valdagni and CJ Talbot. Frontiers in Oncology 2020 Oct 30;10:575909.

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.
P Seibold, A Webb, ME Aguado-Barrera, D Azria, C Bourgier, M Brengues, E Briers, R Bultijnck, P Calvo-Crespo, A Carballo, A Choudhury, A Cicchetti, J Claßen, E Delmastro, AM Dunning, RM Elliott, L Fachal, MP Farcy-Jacquet, P Gabriele, E Garibaldi, A Gómez-Caamaño, S Gutiérrez-Enríquez, DS Higginson, K Johnson, R Lobato-Busto, M Mollà, A Müller, D Payne, P Peleteiro, G Post, T Rancati, T Rattay, V Reyes, BS Rosenstein, D De Ruysscher, MC De Santis, J Schäfer, T Schnabel, E Sperk, RP Symonds, H Stobart, B Taboada-Valladares, CJ Talbot, R Valdagni, A Vega, L Veldeman, T Ward, C Weißenberger, CML West and J Chang-Claude: REQUITE consortium. Radiotherapy and Oncology 2019 Sep;138:59-67.

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study.
RL O'Connell, T Rattay, RV Dave, A Trickey, J Skillman, NLP Barnes, M Gardiner, A Harnett, S Potter and C Holcombe. British Journal of Cancer. 2019 Apr;120(9):883-895.

Genetic variants predict optimal timing of radiotherapy to reduce side-effects in breast cancer patients.
K Johnson, J Chang-Claude, AM Critchley, C Kyriacou, S Lavers, T Rattay, P Seibold, A Webb, C West, RP Symonds and CJ Talbot. Clinical Oncology (R Coll Radiol). 2019 Jan;31(1):9-16.

The patient perspective on radiogenomics testing for breast radiation toxicity.
T Rattay, RP Symonds, S Shokuhi, CJ Talbot and JB Schnur. Clinical Oncology (R Coll Radiol). 2018 Mar;30(3):151-157.



Dr Rattay supervises projects in the areas of:

  • Prediction of treatment toxicity in the breast using clinical and molecular markers
  • Radiogenomics
  • Breast surgery and reconstruction
  • Exploring patients’ views on breast cancer treatments


Dr Rattay teaches modules on the subjects of:

  • MBChB Surgery and Cancer Care Blocks
  • MSc Cancer Molecular Pathology and Therapeutics

Press and media

  • Breast cancer
  • Surgery
  • Radiotherapy
  • Radiogenomics


  • Associate Specialty Study Lead, Royal College of Surgeons of England
  • Member of Mammary Fold Academic & Research Committee
  • Membership of Association of Breast Surgery, British Association of Surgical Oncology, International Radiogenomics Consortium


  • BSc (Hons), University of Bristol
  • MBChB, University of Bristol
  • MMedEd, University of Warwick
  • MRes, University of Leicester
  • PhD, University of Leicester
  • FRCS, Royal College of Surgeons of England
Back to top